Rani Therapeutics
Rani Therapeutics' revenue rose 58.9% to $2 million in fiscal 2025. Its operating margin was −2,346.0%, up from −5,186.2% a year earlier. Free cash flow was −$19 million. The diluted share count rose 132.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Rani Therapeutics lost money in fiscal 2025: a net loss of $30 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 118 | 126 | — | 4 | 19 |
| Debt incl. finance leases | — | 30 | 30 | 25 | 0 |
| Net debt (negative means net cash) | — | −96 | — | 21 | −19 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.8x | 2.3x | 12.6x | 0.0x |
| Interest coverage | −110.7x | −59.2x | −13.0x | −10.6x | −13.2x |
| Current ratio | 45.3x | 21.0x | 6.4x | 1.5x | 4.2x |
| Quick ratio | 45.3x | 21.0x | 6.4x | 1.5x | 4.2x |
Cash flow
Projections
Project Rani Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $50,040 of Rani Therapeutics shares on the open market, and 1 insider sold $301.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 21, 2026 | Mir A ImranDirector, 10% owner | Bought | 36,000 | $0.69 | $24,840 | Form 4 |
| Jul 17, 2026 | Talat ImranChief Executive Officer, Director | Bought | 35,000 | $0.72 | $25,200 | Form 4 |
| Mar 27, 2026 | Alireza JavadiChief Technical Officer | Sold | 386 | $0.78 | $301 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 0 of 8 | 1 of 8 | 4 of 8 |
| Rule of 40 | — | — | −1,092.5% |
| Altman Z'' | −6.10 | −17.06 | −4.67 |
| Accruals ratio | 20.8% | 11.6% | −23.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 0 of 8 | 1 of 8 | 4 of 8 |
Compare
Put Rani Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Rani Therapeutics | FY25 | 58.9% | −2,346.0% | −1,151.4% | −127.1% | — | 4 | |
| Vistagen Therapeutics | FY26 | 161.1% | −5,683.7% | — | — | — | 2 | Compare |
| Dianthus Therapeutics | FY25 | −67.3% | −8,739.3% | −6,349.4% | — | — | — | Compare |
| Lipocine | FY25 | −82.3% | −524.7% | — | — | — | — | Compare |
| Oramed Pharmaceuticals | FY25 | — | −754.4% | −457.7% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 0 | 3 | 0 | 0 | 1 | 2 |
| Revenue growth | — | 488.1% | −100.0% | — | — | 58.9% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 12 | 26 | 37 | 40 | 27 | 20 |
| Operating income | −16 | −52 | −64 | −66 | −53 | −38 |
| Net income | −17 | −8 | −31 | −34 | −30 | −30 |
| Diluted EPS (US$) | — | −0.43 | −1.28 | −1.33 | −1.05 | −0.45 |
| Diluted shares (millions) | — | 20 | 24 | 26 | 28 | 66 |
| Cash flow | ||||||
| Cash from operations | −15 | −32 | −46 | −51 | −36 | −19 |
| Capital expenditure | 1 | 0 | 2 | 1 | 0 | 0 |
| Free cash flow | −16 | −33 | −48 | −52 | −36 | −19 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 23 | 16 | 19 | 16 | 12 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 73 | 118 | 126 | — | 4 | 19 |
| Debt incl. finance leases | 4 | — | 30 | 30 | 25 | 0 |
| Total assets | 79 | 124 | 108 | 58 | 37 | 59 |
| Total liabilities | 8 | 3 | 34 | 32 | 33 | 17 |
| Shareholders' equity | −113 | 47 | 37 | 13 | 2 | 33 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −3,580.9% | −1,899.1% | — | — | −5,186.2% | −2,346.0% |
| Net margin | −3,615.4% | −306.6% | — | — | −2,920.0% | −1,817.1% |
| Free cash flow margin | −3,497.8% | −1,205.4% | — | — | −3,479.0% | −1,151.4% |
| Rule of 40 (growth + FCF margin) | — | −717.3% | — | — | — | −1,092.5% |
| Return on capital | — | — | — | — | — | −127.1% |
| Return on equity | — | — | −72.6% | −136.6% | −404.1% | −169.6% |
| Return on assets | — | −8.2% | −26.3% | −40.9% | −63.5% | −62.3% |
| Net debt to EBITDA | — | — | — | — | — | — |